Clinical development of mTOR inhibitors in breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The mammalian target of rapamycin (mTOR) pathway regulates key cellular processes including translation, metabolism, and autophagy, and is implicated in cancer development.
• mTOR inhibitors have demonstrated efficacy in improving outcomes for hormone receptor-positive and HER2-positive breast cancer patients in randomized trials.

Purpose of the Study:

• To review new perspectives on mTOR inhibitors in breast cancer based on recent clinical trials.
• To analyze the role of the mTOR pathway in resistance to endocrine therapy, trastuzumab, and chemotherapy.
• To discuss the identification of biomarkers for patient stratification in breast cancer treatment.

Main Methods:

• Review of findings from randomized clinical trials involving mTOR inhibitors in breast cancer.
• Analysis of preclinical studies investigating the mTOR pathway's role in treatment resistance.
• Examination of efforts to identify predictive biomarkers for mTOR inhibitor therapy.

Main Results:

• mTOR inhibitors have shown potential in improving patient outcomes in specific breast cancer subtypes.
• The mTOR pathway is implicated in resistance mechanisms against standard breast cancer therapies.
• Biomarker identification is crucial for stratifying patients and optimizing treatment strategies.

Conclusions:

• mTOR inhibitors represent a valuable therapeutic strategy for certain breast cancer patients.
• Understanding mTOR pathway's role in resistance is key to developing more effective treatments.
• Future clinical trials will benefit from biomarker-guided patient selection for personalized breast cancer care.